Avoiding chemotherapy entirely, both drugs taken by mouth
In the quiet arithmetic of clinical trials, 338 people across 29 countries have lent their lives to a question that medicine has long struggled to answer: what comes after hope runs out? HUTCHMED's SAFFRON trial, now fully enrolled, tests whether two oral drugs can outperform chemotherapy for lung cancer patients whose tumors have learned to resist the treatment that once held them at bay. The completion of enrollment marks not an ending but a threshold — one that, by mid-2026, may open a new path for patients facing one of the most lethal and common cancers in the world.
- For patients whose lung cancer has outsmarted targeted therapy, the current fallback — platinum-based chemotherapy — carries a heavy toll in toxicity and diminished quality of life.
- MET-driven resistance, affecting up to half of EGFR-mutated lung cancer patients on TAGRISSO, has created a treatment gap that oncologists have lacked reliable tools to close.
- The SAFFRON trial, spanning 230 sites across 29 countries, has now locked in its 338-patient cohort, setting the stage for results that could redefine second-line care globally.
- The combination already holds regulatory approval in China and FDA Fast Track status in the US, signaling institutional confidence that this approach deserves urgent evaluation.
- Topline data expected in the first half of 2026 will determine whether this chemotherapy-free oral regimen becomes a new standard of care — or returns patients to the drawing board.
On the last day of October, a global clinical trial quietly crossed its finish line — not with fanfare, but with the enrollment of its final patient. HUTCHMED announced that SAFFRON, its Phase III study testing a combination of ORPATHYS and TAGRISSO against chemotherapy, had completed enrollment of 338 patients drawn from more than 230 sites across 29 countries.
The patients in this trial share a specific and difficult circumstance: they carry EGFR-mutated non-small cell lung cancer whose tumors have developed MET-driven resistance to TAGRISSO, the targeted therapy that had initially worked. Between 15 and 50 percent of EGFR-mutated patients eventually face this resistance, and when they do, chemotherapy has historically been the only recourse. SAFFRON asks whether that needs to remain true.
The combination being tested is already familiar in China, where ORPATHYS received approval in June 2025 based on earlier trial data. Both drugs are taken orally, and together they target two separate mechanisms the tumor uses to survive. For patients who have already endured one line of targeted therapy, the prospect of avoiding chemotherapy's side effects carries real weight. The trial's primary endpoint — progression-free survival as assessed by independent blinded reviewers — will determine whether that promise holds.
The FDA has granted SAFFRON Fast Track designation, acknowledging the unmet need this population represents. HUTCHMED expects to report topline results in the first half of 2026, with a medical congress presentation to follow. If the data are favorable, regulatory filings in the United States and other markets will move forward. A companion Chinese trial, SANOVO, testing the same combination in previously untreated patients, completed enrollment just months earlier. The pieces are in place; now comes the waiting.
On October 31st, the last patient was enrolled in a global clinical trial that could reshape how doctors treat a stubborn form of lung cancer. HUTCHMED, a biopharmaceutical company based in Hong Kong and Shanghai, announced the completion of SAFFRON, a Phase III study testing whether two oral drugs—ORPATHYS and TAGRISSO—work better than chemotherapy for patients whose cancer has developed resistance to prior treatment.
The trial enrolled 338 patients screened from more than 230 sites across 29 countries. These were people with a specific type of advanced lung cancer: non-small cell lung cancer that carries an EGFR mutation and shows MET overexpression or amplification. In simpler terms, their tumors had developed a way to resist the standard targeted therapy, TAGRISSO, which had initially worked. The study compares the two-drug combination against platinum-based chemotherapy—the traditional fallback when targeted drugs stop working.
Lung cancer remains the leading cause of cancer death worldwide, accounting for roughly one in five cancer deaths. About 80 to 85 percent of lung cancers are the non-small cell variety. Among patients with the EGFR mutation—which makes them candidates for targeted therapy rather than chemotherapy—somewhere between 15 and 50 percent eventually develop MET-driven resistance, depending on how the tumor is tested. This is the population SAFFRON is designed to help.
The combination being tested is not new to medicine. ORPATHYS, an oral drug that targets the MET receptor, was already approved in China in June 2025 based on results from an earlier trial called SACHI. That approval came after the combination showed strong results in a smaller Phase II study called SAVANNAH, which was presented at the European Lung Cancer Congress in 2025. The data showed high response rates and manageable side effects. TAGRISSO, the partner drug, is a third-generation EGFR inhibitor that has already been used to treat more than one million patients worldwide across various stages of lung cancer.
What makes this combination attractive is that it avoids chemotherapy altogether. Both drugs are taken by mouth. For patients who have already endured one round of targeted therapy and are facing progression, avoiding the toxicity and side effects of chemotherapy is meaningful. The primary measure of success in SAFFRON will be progression-free survival—how long patients live without their cancer worsening—as assessed by independent reviewers blinded to which treatment each patient received.
The U.S. Food and Drug Administration granted SAFFRON Fast Track designation, a status reserved for drugs addressing serious conditions with unmet medical need. That designation accelerates the review process if results are positive. HUTCHMED expects to report the trial's main findings in the first half of 2026, followed by presentation at a major medical conference. If the results are favorable, the company plans to file for regulatory approval in the United States and other markets beyond China.
Two other trials testing this same combination are also underway. SANOVO, a Chinese trial comparing the two-drug combination to TAGRISSO alone in previously untreated patients, completed enrollment in August 2025. The stakes are high: if SAFFRON succeeds, it could establish a new standard of care for a population of patients who currently have limited options once their first targeted therapy fails.
Notable Quotes
This combination represents a promising, chemotherapy-free, all-oral treatment option following progression on an EGFR tyrosine kinase inhibitor— HUTCHMED announcement
The Hearth Conversation Another angle on the story
Why does it matter that this trial just finished enrolling? Isn't that just a procedural milestone?
It matters because enrollment is often the bottleneck. You need 338 patients with a very specific type of cancer—not just any lung cancer, but one with particular genetic markers—and they have to be willing to be randomized to either the new combination or chemotherapy. Getting that many people across 29 countries took time and coordination. Now the clock starts on actually seeing whether the treatment works.
The source says this combination was already approved in China. So why run a global trial if you already know it works?
China approved it based on one trial, SACHI, which showed promise. But regulatory agencies in the U.S. and Europe want their own evidence. They want to see the same benefit replicated in a different population, across different healthcare systems. It's not distrust—it's the standard. And there's also a strategic element: if SAFFRON succeeds, it opens markets worth billions.
What happens to patients in the chemotherapy arm? Doesn't it feel unethical to give people chemotherapy when you might have a better option?
That's the tension at the heart of any trial like this. The researchers genuinely don't know yet which is better. The SAVANNAH data looked good, but it was a smaller, single-arm study—everyone got the combination. SAFFRON is randomized because you need a control group to know if the benefit is real or just what you'd expect anyway. And chemotherapy, while harsh, is proven to work for some patients. The ethics board approved this design because the uncertainty was genuine.
Who benefits if this works? Just wealthy patients in developed countries?
That's the real question. The trial enrolled from 230 sites across 29 countries, so it's genuinely global. But approval and access are different things. If it works, it'll be approved in the U.S., Europe, and probably other markets. Whether patients in lower-income countries can actually afford it or access it—that depends on pricing, manufacturing, and whether companies choose to make it available. The trial itself is global, but the benefit isn't automatically distributed equally.
When will we actually know if this worked?
Mid-2026 at the earliest. That's when they expect to have enough data on how long patients lived without their cancer progressing. Then it goes to a medical conference for presentation, and if it's positive, the regulatory filings begin. So realistically, we're looking at 2027 or 2028 before patients outside of China might have access, assuming everything goes well.